Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validation study of risk-reduction activities after personalized breast cancer education tool in the WISDOM study.
Wang T, Che M, Huilgol YS, Keane H, Goodman D, Soonavala R, Ozanne E, Shieh Y, Belkora JK, Fiscalini AS; Athena Breast Health Network Investigators and Advocate Partners; Esserman LJ. Wang T, et al. Among authors: fiscalini as. NPJ Breast Cancer. 2024 Oct 14;10(1):90. doi: 10.1038/s41523-024-00681-z. NPJ Breast Cancer. 2024. PMID: 39397069 Free PMC article.
Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry.
Huilgol YS, Keane H, Shieh Y, Hiatt RA, Tice JA, Madlensky L, Sabacan L, Fiscalini AS, Ziv E, Acerbi I, Che M, Anton-Culver H, Borowsky AD, Hunt S, Naeim A, Parker BA, van 't Veer LJ; Athena Breast Health Network Investigators and Advocate Partners; Esserman LJ. Huilgol YS, et al. Among authors: fiscalini as. NPJ Breast Cancer. 2021 Aug 3;7(1):102. doi: 10.1038/s41523-021-00306-9. NPJ Breast Cancer. 2021. PMID: 34344894 Free PMC article.
Validation Study on Risk-Reduction Activities after Exposure to a Personalized Breast Cancer Risk-Assessment Education Tool in High-Risk Women in the WISDOM Study.
Wang T, Che M, Huilgol YS, Keane H, Goodman D, Soonavala R, Ozanne E, Shieh Y, Belkora JK, Fiscalini AS; Athena Breast Health Network Investigators and Advocate Partners; Esserman LJ. Wang T, et al. Among authors: fiscalini as. Res Sq [Preprint]. 2023 May 10:rs.3.rs-2787493. doi: 10.21203/rs.3.rs-2787493/v1. Res Sq. 2023. Update in: NPJ Breast Cancer. 2024 Oct 14;10(1):90. doi: 10.1038/s41523-024-00681-z PMID: 37214889 Free PMC article. Updated. Preprint.
The WISDOM study: a new approach to screening can and should be tested.
Esserman L, Eklund M, Veer LV, Shieh Y, Tice J, Ziv E, Blanco A, Kaplan C, Hiatt R, Fiscalini AS, Yau C, Scheuner M, Naeim A, Wenger N, Lee V, Heditsian D, Brain S, Parker BA, LaCroix AZ, Madlensky L, Hogarth M, Borowsky A, Anton-Culver H, Kaster A, Olopade OI, Sheth D, Garcia A, Lancaster R, Plaza M. Esserman L, et al. Among authors: fiscalini as. Breast Cancer Res Treat. 2021 Oct;189(3):593-598. doi: 10.1007/s10549-021-06346-w. Epub 2021 Sep 16. Breast Cancer Res Treat. 2021. PMID: 34529196 No abstract available.
Response to Carter et al.
Eklund M, Broglio K, Yau C, Connor JT, Fiscalini AS, Esserman LJ. Eklund M, et al. Among authors: fiscalini as. JNCI Cancer Spectr. 2020 Mar 5;4(2):pkaa016. doi: 10.1093/jncics/pkaa016. eCollection 2020 Apr. JNCI Cancer Spectr. 2020. PMID: 32373780 Free PMC article. No abstract available.
An online randomized controlled trial, with or without problem-solving treatment, for long-term cancer survivors after hematopoietic cell transplantation.
Syrjala KL, Yi JC, Artherholt SB, Romano JM, Crouch ML, Fiscalini AS, Hegel MT, Flowers MED, Martin PJ, Leisenring WM. Syrjala KL, et al. Among authors: fiscalini as. J Cancer Surviv. 2018 Aug;12(4):560-570. doi: 10.1007/s11764-018-0693-9. Epub 2018 May 5. J Cancer Surviv. 2018. PMID: 29730827 Free PMC article. Clinical Trial.
13 results